Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids Keisuke.

Slides:

Advertisements

Similar presentations

Daniela P. Metz, PhDa, Annette S

Advertisements

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms Anna Slovick, MRCS, Abdel Douiri, PhD,

Immunopathogenesis of human gastrointestinal infection by Anisakis simplex Victoria del Pozo, PhDa, Ignacio Arrieta, MDa, Teresa Tuñon, MD, PhDb, Isabel.

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison.

Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma Makoto Hoshino, MDa, Yutaka Nakamura, MDa,

Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: Comparison with airway eosinophils Julie.

The effect of omalizumab on nasal allergic inflammation

Allergen-specific IgE production of committed B cells from allergic patients in vitro Peter Steinberger, MSca, Barbara Bohlea, Franco di Padova, MDb,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.

Suzana Radulovic, MD, Mikila R. Jacobson, PhD, Stephen R

T lymphocytes in asthma: Bronchial versus peripheral responses

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma

Susan C. Foley, MD, David Préfontaine, MSc, Qutayba Hamid, MD, PhD

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms Anna Slovick, MRCS, Abdel Douiri, PhD,

Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure Margherita Tomassini, MDa, Laura Magrini, MDa, Guido De.

IL-11 expression is increased in severe asthma: Association with epithelial cells and eosinophils Eleanor Minshall, PhDa, Jamila Chakir, PhDb, Michel.

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic.

Expression of IFN-γ–inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases Deborah Miotto,

Evidence for expression of eosinophil-associated IL-12 messenger RNA and immunoreactivity in bronchial asthma Esra Nutku, MDa, Abdelilah Soussi Gounni,

Role of IL-35 in sublingual allergen immunotherapy

Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effects of single allergen challenge Adriaan.

The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells Juha Punnonen, MD, PhD, Hans Yssel, PhD,

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Recruitment of T cells to the lung in response to antigen challenge

Daniela P. Metz, PhDa, Annette S

Effect of ozone and nitrogen dioxide on the release of proinflammatory mediators from bronchial epithelial cells of nonatopic nonasthmatic subjects and.

Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years’ duration Kawa.

Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms Aaron M. Levy, MDa, Hirohito Kita, MDb, Sidney F. Phillips, MDa, Paul.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

IL-9 expression by human eosinophils: Regulation by IL-1β and TNF-α

Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation Alex.

Antigen-specific and nonspecific determinants of cytokine production during topical sensitization of mice to chemical allergens Artin Moussavi, PhDa,

Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma Yasurou Kohno, MDa,

TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced.

Molecular pathology of allergic disease

Allergic rhinitis Journal of Allergy and Clinical Immunology

Loratadine reduces allergen-induced mucosal output of α2-macroglobulin and tryptase in allergic rhinitis Lennart Greiff, MD, PhDa, Carl G.A. Persson,

Blood eosinophils from atopic donors express messenger RNA for the α, β, and γ subunits of the high-affinity IgE receptor (FcϵRI) and intracellular, but.

Chemokines in seasonal allergic rhinitis

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis Matthias Volkmar Kopp, MDa, Jens Brauburger,

Seasonal intestinal inflammation in patients with birch pollen allergy

Prognosis and prediction of response to surgery in allergic patients with chronic sinusitis François Lavigne, MDa, Cong Thu Nguyen, MDa, Lisa Cameron,

Corticosteroids in the treatment of pediatric allergic rhinitis

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis Ellinor Ädelroth, MD, PhDa, Sabina Rak, MD, PhDb,

Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways Gert-Jan Braunstahl, MDa, b, Shelley.

Rame A. Taha, MDa, Eleanor M. Minshall, PhDa, Donald Y. M

Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: Effect of topical corticosteroids Pota Christodoulopoulos, BSca,

Local expression of ϵ germline gene transcripts and RNA for the ϵ heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma Sun Ying,

Food allergen (peanut)–specific T H2 clones generated from the peripheral blood of a patient with peanut allergy Esther C. de Jong, MSca, b, Steven Spanhaak,

IL-4 upregulates FcϵRI α-chain messenger RNA in eosinophils

Cytokine profile in minor salivary glands from patients with bronchial asthma Anne Tsicopoulos, MDa, b, Anne Janin, MDc, Hikmat Akoum, PhDa, Catherine.

IL-4– and IL-5–positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects Luis T. Barata,

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy Kayhan T. Nouri-Aria, PhD, FRCPath, Charles.

Larry C. Borish, MDa, Harold S

Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic.

Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression

Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4,

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response Meri K Tulic, PhD, Pierre-Olivier Fiset,

Diisocyanate antigen–enhanced production of monocyte chemoattractant protein-1, IL- 8, and tumor necrosis factor-α by peripheral mononuclear cells of workers.

Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal.

Pascal Chanez, MDa, Antonio M

Presentation transcript:

Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids Keisuke Masuyama, MDa, Stephen J. Till, PhDa, Mikila R. Jacobson, PhDa, Asma Kamil, MScb, Lisa Cameron, BScb, Sigurdur Juliusson, MDc, Olle Lowhagen, MDd, A.Barry Kay, PhDe, Qutayba A. Hamid, PhDb, Stephen R. Durham, MDa Journal of Allergy and Clinical Immunology Volume 102, Issue 4, Pages 610-617 (October 1998) DOI: 10.1016/S0091-6749(98)70277-5 Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 1 A, Timothy grass pollen (Phleum pratense) counts in Gotenburg during the summer when this study was conducted. B, Median visual analogue symptoms scores over the same period in placebo- (open triangles) and fluticasone-treated (closed triangles) patients with allergic rhinitis. Peak season nasal biopsy specimens were collected at time point indicated. Journal of Allergy and Clinical Immunology 1998 102, 610-617DOI: (10.1016/S0091-6749(98)70277-5) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 2 Effect of fluticasone on numbers of EG2+ eosinophils and CD3+ T cells in nasal epithelium and submucosa. Data shown are for baseline (preseason) and during natural grass pollen allergen exposure (peak season), in placebo- (open circles) and fluticasone-treated (closed circles) patients with allergic rhinitis. Lines represent median values. Within group preseason and peak-season counts were compared by the Wilcoxon test, and differences (peak season minus preseason) between fluticasone- and placebo-treated patients were compared by using the Mann-Whitney U test. Journal of Allergy and Clinical Immunology 1998 102, 610-617DOI: (10.1016/S0091-6749(98)70277-5) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 3 Autoradiographs of cryostat sections of nasal biopsy specimens collected from a patient receiving placebo during the pollen season. Sections were hybridized with a 35 S-labeled antisense IL-5 riboprobe (A) and a 35 S-labeled sense IL-5 riboprobe (negative control) (B). Journal of Allergy and Clinical Immunology 1998 102, 610-617DOI: (10.1016/S0091-6749(98)70277-5) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 4 Effect of fluticasone on numbers of IL-5 and GM-CSF mRNA–expressing cells in nasal submucosa. Data shown are for baseline (preseason) and during natural grass pollen allergen exposure (peak season), in fluticasone- (open circles) and placebo-treated (closed circles) patients with allergic rhinitis. Lines represent median values. Differences (peak-season minus preseason) between fluticasone- and placebo-treated patients were compared by using the Mann-Whitney U test. Journal of Allergy and Clinical Immunology 1998 102, 610-617DOI: (10.1016/S0091-6749(98)70277-5) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 5 effects of fluticasone on in vitro secretion of il-5 protein by allergen-stimulated peripheral blood t cells. PBMCs were stimulated with Phleum pratense at 5 × 106 cells/ml, and supernatants were collected after 6 days for measurement of il-5 by ELISA. data points represent mean values (+ SE) of 5 atopic subjects (closed circles). Open circles represent il-5 production in presence of drug vehicle controls. *P < .05 versus control culture (no fluticasone). Journal of Allergy and Clinical Immunology 1998 102, 610-617DOI: (10.1016/S0091-6749(98)70277-5) Copyright © 1998 Mosby, Inc. Terms and Conditions